This article refers to:
Zeng M, Wang Y, Liu M, et al. Int J Nanomedicine. 2023;18:6503–6525.
The authors have advised that Figure 2 on page 6510 was published in error. The correct Figure 2 is as follows.
Figure 2 HM-CDs significantly improved blood-brain barrier (BBB) permeability. HM-CD-1 has an ultra-tiny size and abundance surface functional groups. The covalent binding of HM-CD-2 to the drug facilitates passive transport of the drug. HM-CD-3 has a strong affinity for the BBB endothelial cell membrane.
The authors apologize for this error.